Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: A potential pharmacologic mechanism and therapeutic advantages

European Journal of Pharmacology

Volumn 726, Issue 1, 2014, Pages 49-56

  Lee, Yonghyun ^a,b   Kim, Wooseong ^a   Hong, Sungchae ^a   Park, Huijeong ^a   Yum, Soohwan ^a   Yoon, Jeong Hyun ^a   Jung, Yunjin ^a  

^a Pusan National University   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Cardiovascular toxicity; Celecoxib; Colon specific prodrug; Inflammatory bowel disease; NF kappaB

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PRODRUG; PYRAZOLE DERIVATIVE; SULFONAMIDE; TRINITROBENZENESULFONIC ACID;

ANIMAL; BLOOD; CELL LINE; CHEMICALLY INDUCED; COLITIS; COLON; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MOUSE; RAT;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; CELL LINE; COLITIS; COLON; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; PRODRUGS; PYRAZOLES; RATS; SULFONAMIDES; TRINITROBENZENESULFONIC ACID;

EID: 84893455385     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.01.011     Document Type: Article

References (32)

1. I. Atreya, R. Atreya, and M.F. Neurath NF-kappaB in inflammatory bowel disease J. Intern. Med. 263 2008 591 596
2. J.M. Brophy Cardiovascular risk associated with celecoxib N. Engl. J. Med. 352 2005 2648 2650
3. M.A. Buerkle, S. Lehrer, H.Y. Sohn, P. Conzen, U. Pohl, and F. Krotz Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo Circulation 110 2004 2053 2059 (Pubitemid 39331921)
4. B. Caldwell, S. Aldington, M. Weatherall, P. Shirtcliffe, and R. Beasley Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis J. R Soc. Med. 99 2006 132 140
5. A.M. Carothers, J.S. Davids, B.C. Damas, and M.M. Bertagnolli Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis Cancer Res. 70 2010 4433 4442
6. S. Cuzzocrea, E. Mazzon, I. Serraino, L. Dugo, T. Centorrino, A. Ciccolo, L. Sautebin, and A.P. Caputi Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats Eur. J. Pharmacol. 431 2001 91 102 (Pubitemid 33082156)
7. A. El-Medany, A. Mahgoub, A. Mustafa, M. Arafa, and M. Morsi The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats Eur. J. Pharmacol. 507 2005 291 299 (Pubitemid 40126866)
8. M. Funakoshi-Tago, T. Shimizu, K. Tago, M. Nakamura, H. Itoh, Y. Sonoda, and T. Kasahara Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB Biochem. Pharmacol. 76 2008 662 671
9. D.W. Gilroy, and P.R. Colville-Nash New insights into the role of COX 2 in inflammation J. Mol. Med. (Berl) 78 2000 121 129 (Pubitemid 30337493)
10. S. Giri, R. Rattan, A.K. Singh, and I. Singh The 15-deoxy-delta12,14- prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF- kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma J. Immunol. 173 2004 5196 5208 (Pubitemid 39387803)
11. R.A. Hegazi, H.H. Mady, M.F. Melhem, A.R. Sepulveda, M. Mohi, and H.M. Kandil Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice Inflamm. Bowel Dis. 9 2003 230 236
12. S. Hong, S. Yum, H.J. Yoo, S. Kang, J.H. Yoon, D. Min, Y.M. Kim, and Y. Jung Colon-targeted cell-permeable NFkappaB inhibitory peptide is orally active against experimental colitis Mol. Pharmacol. 9 2012 1310 1319
13. Y. Jung, and Y.M. Kim What should be considered on design of a colon-specific prodrug? Expert Opin. Drug Deliv. 7 2010 245 258
14. Y. Lee, J. Kim, H. Kim, S. Kang, J.H. Yoon, D.D. Kim, Y.M. Kim, and Y. Jung N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with impro ved therapeutic properties J. Pharm. Sci. 101 2012 1831 1842
15. Q. Li, and I.M. Verma NF-kappaB regulation in the immune system Nat. Rev. Immunol. 2 2002 725 734
16. M. Lopez-Parra, J. Claria, E. Titos, A. Planaguma, M. Parrizas, J.L. Masferrer, W. Jimenez, V. Arroyo, F. Rivera, and J. Rodes The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin J. Hepatol. 42 2005 75 81 (Pubitemid 40038903)
17. U. Mahadevan, E.V. Loftus Jr., W.J. Tremaine, and W.J. Sandborn Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease Am. J. Gastroenterol. 97 2002 910 914 (Pubitemid 34408247)
18. R. Matuk, J. Crawford, M.T. Abreu, S.R. Targan, E.A. Vasiliauskas, and K.A. Papadakis The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease Inflamm. Bowel Dis. 10 2004 352 356 (Pubitemid 39029177)
19. D. Mukherjee Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events Biochem. Pharmacol. 63 2002 817 821 (Pubitemid 34242993)
20. D. Mukherjee, S.E. Nissen, and E.J. Topol Risk of cardiovascular events associated with selective COX-2 inhibitors J. Am. Med. Assoc. 286 2001 954 959 (Pubitemid 33010342)
21. M.F. Neurath, C. Becker, and K. Barbulescu Role of NF-kappaB in immune and inflammatory responses in the gut Gut. 43 1998 856 860 (Pubitemid 28539668)
22. M. Okayama, S. Hayashi, Y. Aoi, H. Nishio, S. Kato, and K. Takeuchi Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats Dig. Dis. Sci. 52 2007 2095 2103 (Pubitemid 47246503)
23. J.A. Oviedo, and P.C. Schroy 3rd Does celecoxib use increase the risk of cardiovascular events? Gastroenterology 129 2005 1348 1350 (Pubitemid 41446873)
24. B.K. Reuter, S. Asfaha, A. Buret, K.A. Sharkey, and J.L. Wallace Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2 J. Clin. Invest. 98 1996 2076 2085 (Pubitemid 26376296)
25. F. Sanchez-Munoz, A. Dominguez-Lopez, and J.K. Yamamoto-Furusho Role of cytokines in inflammatory bowel disease World J. Gastroenterol. 14 2008 4280 4288
26. W.J. Sandborn, W.F. Stenson, J. Brynskov, R.G. Lorenz, G.M. Steidle, J.L. Robbins, J.D. Kent, and B.J. Bloom Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study Clin. Gastroenterol. Hepatol. 4 2006 203 211 (Pubitemid 43199691)
27. S. Shishodia, D. Koul, and B.B. Aggarwal Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis J. Immunol. 173 2004 2011 2022 (Pubitemid 38971638)
28. V.R. Sinha, and R. Kumria Polysaccharides in colon-specific drug delivery Int. J. Pharm. 224 2001 19 38 (Pubitemid 32706482)
29. V.R. Sinha, and R. Kumria Microbially triggered drug delivery to the colon Eur. J. Pharm. Sci. 18 2003 3 18 (Pubitemid 36120550)
30. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A. Zauber, E. Hawk, and M. Bertagnolli Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N. Engl. J. Med. 352 2005 1071 1080 (Pubitemid 40365348)
31. Y.J. Surh, H.K. Na, J.M. Park, H.N. Lee, W. Kim, I.S. Yoon, and D.D. Kim 15-Deoxy-Delta(1)(2),(1)(4)-prostaglandin J(2), an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling Biochem. Pharmacol. 82 2011 1335 1351
32. J.L. Wallace COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation Sci. World J. 6 2006 577 588 (Pubitemid 43793980)